Market Highlights

Increasing prevalence of congenital adrenal hyperplasia and genetic disorders has boosted the growth of the market. Many government organization is helping the manufacturer by providing funds for research. Additionally, increasing need for better treatment, and increasing government support has driven the global market. However, limited and high cost of treatment options may sustain the growth of the market over the assessment period. Recent advances in the molecular genetic analysis have created a huge opportunity for the market development.

A congenital adrenal hyperplasia is a group of genetic conditions limiting hormone production in the adrenal glands. The exact cause of the disorder is still unknown, however, genetic disorders and other external factors are thought to be responsible for causing this disorder. A wide range of drugs are available for the treatment of this disorder, however, no precise treatment is available to cure the disease

The global congenital adrenal hyperplasia market is expected to grow at a CAGR of ~ 7.1 % during the forecast period 2017-2023.

Regional Analysis

The Americas command a major share of the market owing to the large patient population, growing prevalence of congenital adrenal hyperplasia, and strong government support for research development. Europe accounts for the second leading market across the globe, which is followed by Asia Pacific. Strong government support, availability of funds for research and high healthcare expenditure drives the growth of the market. Asia Pacific is the fastest growing market. India and China are the key contributors to the market growth due to the presence of the huge opportunity for development of the market, rapidly growing economy, and increasing healthcare expenditure. Additionally, increasing government support have fuelled the growth of the market in Asia Pacific.

The Middle East Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition in African region. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East African market owing to a well-developed economy and high healthcare spending.

Segmentation

The global congenital adrenal hyperplasia market is segmented on the basis of types, diagnosis treatment and end users.

On the basis of types, the market is segmented into classic CAH, and non-classic CAH.

On the basis of diagnosis treatment, the market is segmented into diagnosis and treatment. Diagnosis is further segmented into amniocentesis, chorionic villus sampling, blood and urine tests, gene testing, physical exam, and others. Treatment is sub-segmented into medications and surgery. Medications are again segmented into glucocorticoids, mineralocorticoids, salt supplements, and others.

On the basis of end users, the market is segmented into hospital, clinics and others.

Key Players

Some of key the players in the market are Neurocrine Biosciences, Inc. (U.S.), Fusion IP plc (U.K), Novartis AG (Switerzland), Mitsubishi Chemical Holdings Corporation (Japan), Johnson Johnson (U.S.), GlaxoSmithKline Plc (U.S.), Cadila healthcare (India), Sanofi (France), Macleods Pharmaceuticals (India), GlaxoSmithKline Plc. (U.K),  Allergan (Ireland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K), and Merck Co., Inc. (U.S.)